133091-81-3

Basic information

• Product Name: 7-Quinolinamine,5,6,7,8-tetrahydro-(9CI)
• Synonyms: 7-Quinolinamine,5,6,7,8-tetrahydro-(9CI);5,6,7,8-Tetrahydroquinolin-7-aMine
• CAS NO: 133091-81-3
• Molecular Formula: C₉H₁₂N₂
• Molecular Weight: 148.208
• Product Categories: PYRIDINE;AMINEPRIMARY
• Mol File: 133091-81-3.mol

Chemical Properties

• Boiling Point: 264.0±40.0 °C(Predicted)
• Appearance: /
• Density: 1.081±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 9.00±0.20(Predicted)
• CAS DataBase Reference: 7-Quinolinamine,5,6,7,8-tetrahydro-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Quinolinamine,5,6,7,8-tetrahydro-(9CI)(133091-81-3)
• EPA Substance Registry System: 7-Quinolinamine,5,6,7,8-tetrahydro-(9CI)(133091-81-3)

Safety Data

• Hazardous Substances Data: 133091-81-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
7-Quinolinamine,5,6,7,8-tetrahydro-(9CI) is used as a building block for the synthesis of pharmaceuticals due to its versatile chemical properties and potential therapeutic effects. It is particularly of interest for the development of anti-cancer agents, as it has been studied for its ability to inhibit tumor growth and progression.
Used in Agrochemical Industry:
In the agrochemical industry, 7-Quinolinamine,5,6,7,8-tetrahydro-(9CI) is utilized as a precursor in the synthesis of agrochemicals, contributing to the development of effective pesticides and other agricultural chemicals.
Used in Anticancer Applications:
7-Quinolinamine,5,6,7,8-tetrahydro-(9CI) is employed as a potential anti-cancer agent, exhibiting inhibitory effects on tumor growth and progression. Its potential as a therapeutic agent is currently under investigation.
Used in Antimicrobial Applications:
7-Quinolinamine,5,6,7,8-tetrahydro-(9CI) is used as an antimicrobial agent, demonstrating effectiveness against various microorganisms, making it a valuable component in the development of new antimicrobial drugs and treatments.
Used in Antioxidant Formulations:
7-Quinolinamine,5,6,7,8-tetrahydro-(9CI) is used as an antioxidant, with potential applications in the formulation of products designed to prevent oxidative damage and related diseases.
Used in Neurodegenerative Disease Treatment:
As an inhibitor of acetylcholinesterase, 7-Quinolinamine,5,6,7,8-tetrahydro-(9CI) is of interest for the treatment of neurodegenerative diseases, where it may help slow the progression of cognitive decline by maintaining acetylcholine levels in the brain.

Upstream product

• 24334-23-4 5,6-dihydroquinoline 
• 185510-52-5 5-(N-acetylamino)-5,6,7,8-tetrahydroquinoline 
• 298182-09-9 N-(5,6,7,8-tetrahydroquinolin-7-yl)acetamide 
• 133092-40-7 N-(1-Phenyl-ethyl)-N-(5,6,7,8-tetrahydro-quinolin-7-yl)-hydroxylamine 
• 138589-23-8 O-Benzyl-N-(5,6,7,8-tetrahydro-quinolin-7-yl)-hydroxylamine 

Downstream Products

• 405058-77-7 {4-[(5,6,7,8-Tetrahydro-quinolin-7-ylamino)-methyl]-benzyl}-carbamic acid tert-butyl ester 

Relevant articles and documents

Chemokine receptor binding heterocyclic compounds

This invention relates to a novel class of heterocyclic compounds that bind chemokine receptors, inhibiting the binding of their natural ligands thereby. These compounds result in protective effects against infection by HIV through binding to chemokine receptors, including CXCR4 and CCR5, thus inhibiting the subsequent binding by these chemokines. The present invention provides a compound of Formula I wherein, W is a nitrogen atom and Y is absent or, W is a carbon atom and Y═H; R1to R7may be the same or different and are independently selected from hydrogen or straight, branched or cyclic C1-6alkyl; R8is a substituted heterocyclic group or a substituted aromatic group Ar is an aromatic or heteroaromatic ring each optionally substituted at single or multiple, non-linking positions with electron-donating or withdrawing groups; n and n′ are independently, 0-2; X is a group of the formula: Wherein, Ring A is an optionally substituted, saturated or unsaturated 5 or 6-membered ring, and P is an optionally substituted carbon atom, an optionally substituted nitrogen atom, sulfur or oxygen atom. Ring B is an optionally substituted 5 to 7-membered ring. Ring A and Ring B in the above formula can be connected to the group W from any position via the group V, wherein V is a chemical bond, a (CH2)n″group (where n″=0-2) or a C═O group. Z is, (1) a hydrogen atom, (2) an optionally substituted C1-6alkyl group, (3) a C0-6alkyl group substituted with an optionally substituted aromatic or heterocyclic group, (4) an optionally substituted C0-6alkylamino or C3-7cycloalkylamino group, (5) an optionally substituted carbonyl group or sulfonyl. These compounds further include any pharmaceutically acceptable acid addition salts and metal complexes thereof and any stereoisomeric forms and mixtures of stereoisomeric forms thereof.

PYRIDINE DERIVATIVES

Pyridine derivatives of formula STR1 their heteroaromatic N-oxides and their pharmaceutically acceptable acid addition salts are disclosed. In the formula z is 0, 1 and 2 and R, R 1, R 2 and R. sup.2 have specified meanings. The compounds exhibit activity

7-Amino-5,6,7,8-tetrahydroquinolines. Preparation from 5,6-dihydroquinoline and nitrogen nucleophiles

The preparation of 7-amino-5,6,7,8-tetrahydroquinolines is described. These agents are 5-HT(1A) receptor ligands related to 8-OH-DPAT.